News from AACR 2024: Wednesday’s highlights
Drug Discovery World
APRIL 11, 2024
In clonogenic assay, BRCA2-deficient DLD1 cells were ~15-fold more sensitive to FEN1 inhibition than their isogenic BRCA2-wild-type counterparts (EC50 of 350nM and 5µM, respectively), confirming the increased susceptibility of HR deficient cancer cells to FEN1 inhibition. And thanks to the city of San Diego for its hospitality.”
Let's personalize your content